Products from TransMed7's technology pipeline currently under development are designed to address critical healthcare needs in medical fields such as breast health; soft tissue surgery, including small or fragile tissues and challenging surgical spaces, with endoscopy, laparoscopy, and robotics applications; bone marrow biopsy and harvest; interventional cardiology; and minimally invasive peripheral vascular procedures.
"This new strategic partnership with Peridot enables TransMed7 to launch new products such as our Concorde and Martinet technologies directly into the market immediately following FDA clearance. Peridot was our contract manufacturer for our SpeedBird platform needle sets, and we are excited to be expanding our relationship with Peridot for timed product commercial release in significant quantities for strategic market penetration," said Eugene H. Vetter, TransMed7's Co-Founder and CEO.
TransMed7 is focused on the development of minimally invasive medical devices. With particular expertise in both oncologic and cardiovascular disease, the company and its team of clinicians, scientists, and engineers have developed a portfolio of next-generation platform devices.
Peridot offers complete end-to-end precision manufacturing and clean room assembly services to a wide range of industries. With over twenty years' experience with device fabrication and precision miniature and micro-miniature component assembly, the company can design, prototype, test and deliver products with precision and versatility.
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Alvotech and Teva secure US launch date for Eylea biosimilar AVT06
Egetis initiates rolling US NDA for Emcitate in MCT8 deficiency
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
BiBBInstruments reports additional US orders during targeted EndoDrill GI launch
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
Black Buffalo partners with Sanova to support regulatory strategy and scientific innovation
Nicox completes key data package for NCX 470 NDA submissions
Immusoft's ISP-002 granted US FDA Orphan Drug Designation in MPS II
Orphan Therapeutics Accelerator signs MoU with Fondazione Telethon
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin